Pulse Biosciences, INC 8-K filings

Pulse Biosciences, Inc. has entered into an Equity Distribution Agreement with Mizuho Securities USA LLC to offer and sell up to $75 million of its common stock.

Pulse Biosciences announced its NANOPULSE-AF pivotal study for atrial fibrillation treatment has surpassed its enrollment midpoint, demonstrating strong site enthusiasm and rapid patient recruitment.

Pulse Biosciences announces plans to redeem outstanding common stock warrants, with a deadline for exercise set for July 13, 2026.

Pulse Biosciences' Board approved resolutions allowing TD Securities to sell common stock to affiliates, with potential purchases by key executives.

Pulse Biosciences announced Q1 2026 financial results and accelerated enrollment timelines for its pivotal cardiac catheter IDE trial, NANOPULSE-AF.

Pulse Biosciences announced positive late-breaking clinical data from its nPulse Cardiac Catheter System feasibility study, showing sustained high procedural success and efficiency in treating atrial fibrillation.

Pulse Biosciences released an updated investor presentation detailing progress on its nsPFA cardiac catheter and 2026 strategic objectives.

Pulse Biosciences announced the appointment of Liane R. Teplitsky as Chief Operating Officer, effective April 8, 2026, and detailed her compensation package including stock options and RSUs tied to performance milestones.

Pulse Biosciences has enrolled the first patients in its NANOPULSE-AF pivotal study evaluating the nPulse Cardiac Catheter System for atrial fibrillation.

Pulse Biosciences' Compensation Committee awarded Chief Technology Officer Darrin R. Uecker 100,000 restricted stock units for his leadership in atrial fibrillation product development.

Pulse Biosciences announced a strategic realignment to prioritize and accelerate its nPulse Cardiac Catheter Ablation System development following exceptional long-term clinical data for AFib treatment.

Pulse Biosciences announces the first patient enrollments in a feasibility study for its Vybrance System to treat papillary thyroid microcarcinoma.

Pulse Biosciences announced the immediate resignation of its Chief Commercial Officer, Kevin P. Danahy, effective February 27, 2026.

Pulse Biosciences announced the immediate resignation of Chief Commercial Officer Kevin P. Danahy, effective February 27, 2026.

Pulse Biosciences announced significant clinical progress in its atrial fibrillation ablation programs and reported its fourth quarter and full year 2025 financial results, showing increased revenue but also higher net losses.

Pulse Biosciences entered a new equity distribution agreement with TD Securities (USA) LLC for up to $59,976,196 in common stock, replacing a prior facility.

Pulse Biosciences, Inc. announced it has posted an updated investor presentation detailing progress in its nPulse product development programs.

Pulse Biosciences strengthens its board with the appointment of Maria Sainz, a seasoned healthcare technology executive, effective January 9, 2026.

Pulse Biosciences announced FDA Investigational Device Exemption approval to initiate its NANOPULSE-AF clinical study for paroxysmal atrial fibrillation treatment.

Pulse Biosciences, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all director nominees were elected, the independent auditor was ratified, and executive compensation was approved on an advisory basis.

Pulse Biosciences announced a research collaboration with MD Anderson Cancer Center to study its nPulse Vybrance Percutaneous Electrode System for thyroid cancer treatment, with FDA approval for a first-in-human study.

Pulse Biosciences, Inc. posted an updated investor presentation detailing recent progress in its nPulse product development programs.

Pulse Biosciences reported initial revenue of $86 thousand in Q3 2025 from its nPulse Vybrance system, alongside increased GAAP and non-GAAP net losses and higher operating expenses as it advances clinical trials and commercialization efforts.

Pulse Biosciences announced the enrollment of the first patient in its NANOCLAMP AF clinical trial, evaluating its nPulse Cardiac Surgical System for atrial fibrillation.

Pulse Biosciences announced positive late-breaking clinical study results for its nPulse Cardiac Surgical System in treating atrial fibrillation, demonstrating high success rates and safety.

Pulse Biosciences, Inc. stockholders approved an amendment to the 2017 Equity Incentive Plan and ratified previously granted equity awards at a special meeting.

Pulse Biosciences announced FDA Investigational Device Exemption approval to begin its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for atrial fibrillation treatment.

Pulse Biosciences announced the successful enrollment and initial procedures in its PRECISE-BTN clinical study for benign thyroid nodules using its nsPFA Percutaneous Electrode System.

Pulse Biosciences announced the publication of positive First-In-Human clinical data for its CellFX nsPFA Percutaneous Electrode System in treating benign thyroid nodules, showing significant size reduction and no scarring.

Pulse Biosciences reported increased losses and expenses in Q2 2025, despite significant clinical progress in its nsPFA technology programs.